课题基金 / 基金详情

Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial

Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial
醛固酮拮抗剂在终末期肾病中保护心脏(第 2 阶段)试验
批准号:
333015
负责人:
Walsh Michael W
金额:
$7.29万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2015
资助国家:
加拿大
项目状态:
已结题
起止时间:
2015-04-01 至 2016-04-01

项目摘要

项目成果

Walsh Michael W的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Forty percent of patients that require dialysis for kidney failure die within three years mostly due to heart disease. Spironlactone is a drug that is very effective at reducing heart related deaths and hospitalizations in patients with heart failure that
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glucocorticoids or Avacopan in peopLe with high-risk renal Anti-Neutrophil cytoplasm antibody associated vasculitis Trial (GALANT) - Pilot
  • 批准号:
    489796
  • 项目类别:
    Operating Grants
  • 资助金额:
    $37.9万
  • 财政年份:
    2023
  • 负责人:
    Walsh Michael W
  • 依托单位:
Aldosterone blockade for Health Improvement Evaluation in End-stage kidney disease: Extension
  • 批准号:
    461992
  • 项目类别:
    Operating Grants
  • 资助金额:
    $88.05万
  • 财政年份:
    2022
  • 负责人:
    Walsh Michael W
  • 依托单位:
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: extended follow-up of a randomized controlled trial
  • 批准号:
    322606
  • 项目类别:
    Operating Grants
  • 资助金额:
    $24.76万
  • 财政年份:
    2015
  • 负责人:
    Walsh Michael W
  • 依托单位:
Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial
  • 批准号:
    310286
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2014
  • 负责人:
    Walsh Michael W
  • 依托单位:
海外基金